Intravenous Injection Of NMN Increases NAD+ Levels in Brain
The team of Professor Miao Chaoyu from the Pharmacology Teaching and Research Section of Naval Medical University found by intravenous injection of a large dose of 2g/kg of NMN to normal mice and mice with ischemic stroke caused by middle cerebral artery occlusion:
After NMN injection, serum NMN levels in mice rose sharply and then decreased rapidly within 15 minutes, while NAD+ levels remained unchanged during the 30-minute observation period.
Over time, NMN and NAD+ accumulated in various tissues and organs including the brain, especially the highest concentration in the kidney, which may be one of the reasons why NMN has the potential to become a "good medicine for kidney protection".
In addition, 24 hours after NMN injection in ischemic stroke mice, the cerebral infarction area was smaller than before; and within 14 days after injection, large doses of NMN did not cause any acute toxicity in mice.
This study is the first to determine the distribution of intravenous nicotinamide mononucleotide (NMN) and its metabolite nicotinamide adenine dinucleotide (NAD) in normal and ischemic stroke mice, and to investigate the effect of NMN on deficient Therapeutic effect of hemorrhagic cerebral infarction and the acute toxicity of NMN after intravenous administration.
Previous: same medicine, why there are different dosage forms such as capsules, tablets and granules?
Next: Time Limit for disintegration of Health Foods of Tablet or Capsule
by GSHWORLD
GSH Bio Tech is China Biological API Manufacturer. China NMN powder suppliers & best NMN raw material Factory.
